Holen Sie sich die Stockscreener-App
267.49
0.75%
1.98
Handel nachbörslich:
267.49
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Labs /US Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Charles River Laboratories International Inc (CRL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Charles River Laboratories International Inc - TradingKey
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories International Inc (CRL) Institutional Confidence - TradingKey
TradingKey - TradingKey
CRL|Charles River Laboratories International Inc|Price:228.000|Chg%:+3.700 - TradingKey
Charles River Laboratories International Inc (CRL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRL|Charles River Laboratories International Inc|Price:224.200|Chg%:-2.380 - TradingKey
ETFs Investing in Charles River Laboratories International, Inc. Stocks - TradingView
Charles River Labs stock trades around recent lows as investors weigh 2024 guidance and Discovery se - Ad-hoc-news.de
Charles River Laboratories International (CRL) Could Be 28% Undervalued On Its New Collaboration - simplywall.st
Q3 2025 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories International, Inc. Revenue Breakdown – NYSE:CRL - TradingView
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised - TradingView
CRL|Charles River Laboratories International Inc|Price:226.580|Chg%:-2.740 - TradingKey
Charles River Laboratories International Inc (CRL) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Charles River Laboratories Gains as Analysts Turn More Constructive Ahead of Earnings - Quiver Quantitative
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
CRL stock steadies as Charles River Laboratories focuses on growth after recent earnings - Ad-hoc-news.de
Charles River Laboratories stock hits 52-week high at $238.46 By Investing.com - Investing.com Nigeria
Charles River Laboratories stock hits 52-week high at $238.46 - Investing.com
Charles River Laboratories International Inc. Stock Advances 4.8%, Outperforms Peers - Bitget
Charles River Labs stock reflects mixed outlook as guidance reset follows scrutiny on Cambodian supp - AD HOC NEWS
CRL4900988 Bond Risk Profile - TradingView
Charles River stock edges higher as guidance and drug development demand frame 2026 outlook - AD HOC NEWS
CRL4900988 Bond Coupon Profile — Rate & Payments - TradingView
Price to sales forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView
Charles River Laboratories Earnings Preview: What to Expect - webull.com
Charles River Labs stock steadies as investors weigh recent earnings trends and outsourcing demand - AD HOC NEWS
CRL5145814 Bond Risk Profile - TradingView
CLSA downgrades Charles River Labs stock rating on valuation By Investing.com - Investing.com Nigeria
Charles River Laboratories (CRL): Investor Outlook Reveals Promising Upside Amidst Sector Challenges - DirectorsTalk Interviews
CLSA downgrades Charles River Labs stock rating on valuation - Investing.com
Charles River Labs stock steadies as revenue growth offsets regulatory headwinds - AD HOC NEWS
CRL5145814 Bond Coupon Profile — Rate & Payments - TradingView
Charles River Labs stock trades steady as recent revenue growth and margin trends frame investor foc - AD HOC NEWS
CRL4900987 Bond Risk Profile - TradingView
Charles River Labs stock reflects recent earnings trends and regulatory overhang - AD HOC NEWS
CRL4900987 Bond Coupon Profile — Rate & Payments - TradingView
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now? - Yahoo Finance
How Charles River’s Expanded GMP NGS Role in ALA-101 Testing Will Impact Charles River (CRL) Investors - simplywall.st
Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued? - Yahoo Finance
Charles River Labs stock trades steady as recent earnings and guidance frame valuation - AD HOC NEWS
Charles River Labs stock holds support as investors wait for fresh numbers. - Ad Hoc News
Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin? - Yahoo Finance
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Charles River Laboratories (CRL) to Report Q2 2026 Earnings on A - GuruFocus
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
Cell-Based Assay Services for Preclinical Use Only Global - GlobeNewswire
CRL5145816 Bond Risk Profile - TradingView
CRL5145816 Bond Coupon Profile — Rate & Payments - TradingView
Charles River Labs stock reflects steady demand for preclinical research services - ad-hoc-news.de
Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating - Moomoo
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $237.79, Implies 2% Upside - TradingView
Charles River to Provide GMP NGS Services to Arovella - Contract Pharma
BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 - Moomoo
Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics - marketscreener.com
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $235.64, Implies 1% Upside - TradingView
Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating - Moomoo
Charles River partners with Arovella on cell therapy testing By Investing.com - Investing.com South Africa
0.06%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):